Trial Profile
Single and multiple dose pharmacokinetics of a modified-release (MR) formulation of the mGluR5 antagonist mavoglurant (AFQ056) in healthy Japanese subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2013
Price :
$35
*
At a glance
- Drugs Mavoglurant (Primary)
- Indications Drug-induced dyskinesia; Parkinson's disease
- Focus Pharmacokinetics
- 22 Jul 2013 New trial record
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.